Document Detail


Gastric acid hypersecretory states: recent insights and advances.
MedLine Citation:
PMID:  19903418     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Gastric acid hypersecretory states are characterized by basal hypersecretion of gastric acid and historically include disorders associated with hypergastrinemia, hyperhistaminemia, and those of unknown etiology. Although gastric acid secretion is infrequently measured, it is important to recognize the role of gastric hypersecretion in the symptoms of these disorders because they share several features of pathogenesis and treatment. In this article, recent important articles reporting insights into their diagnosis, pathogenesis, and treatment are reviewed. Particular attention is paid to Zollinger-Ellison syndrome, because it has the most extreme acid hypersecretion of this group of disorders and because numerous recent articles deal with various aspects of the diagnosis, molecular pathogenesis, and treatment of the gastrinoma itself or the acid hypersecretion. Two new hypersecretory disorders are reviewed: rebound acid hypersecretion after the use of proton pump inhibitors and acid hypersecretion with cysteamine treatment in children with cystinosis.
Authors:
Nauramy Osefo; Tetsuhide Ito; Robert T Jensen
Related Documents :
680508 - Gastric and esophageal dysfunction after ingestion of acid.
11468028 - Effect of centrally administered prolactin on gastric and duodenal ulcers in rats.
6826108 - Effects of bombesin on gastrin and gastric acid secretion in patients with duodenal ulcer.
7250898 - The "internal leak" as a possible cause in the pathogenesis of peptic ulcer.
15294438 - Juvenile sea bass biotransformation, genotoxic and endocrine responses to beta-naphthof...
12615068 - Dykellic acid inhibits drug-induced caspase-3-like protease activation.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural; Review    
Journal Detail:
Title:  Current gastroenterology reports     Volume:  11     ISSN:  1534-312X     ISO Abbreviation:  Curr Gastroenterol Rep     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-11     Completed Date:  2010-02-12     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  100888896     Medline TA:  Curr Gastroenterol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  433-41     Citation Subset:  IM    
Affiliation:
Digestive Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9C-103, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cystamine / adverse effects,  therapeutic use
Cystinosis / drug therapy
Enzyme Inhibitors / adverse effects,  therapeutic use
Gastric Acid / secretion*
Gastrins / metabolism
Histamine / metabolism
Humans
Proton Pump Inhibitors / adverse effects
Stomach Diseases / chemically induced*,  diagnosis,  physiopathology*,  therapy
Zollinger-Ellison Syndrome / physiopathology
Grant Support
ID/Acronym/Agency:
Z01 DK053200-16/DK/NIDDK NIH HHS; Z01 DK053200-17/DK/NIDDK NIH HHS; Z01 DK053215-01/DK/NIDDK NIH HHS; Z01 DK053215-02/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Gastrins; 0/Proton Pump Inhibitors; 51-45-6/Histamine; 51-85-4/Cystamine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progre...
Next Document:  Gut sensing mechanisms.